Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever

Ugurlu S., Hacioglu A., Adibnia Y., HAMURYUDAN V., Ozdogan H.

ORPHANET JOURNAL OF RARE DISEASES, cilt.12, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1186/s13023-017-0642-0
  • Dergi Adı: ORPHANET JOURNAL OF RARE DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Familial Mediterranian fever, Tocilizumab, AA amyloidosis, ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, NEPHROTIC SYNDROME, DISEASE, ARTHRITIS, MULTICENTER, REMISSION, EFFICACY, CRITERIA, THERAPY, PROTEIN
  • Erciyes Üniversitesi Adresli: Hayır

Özet

Background: There is no established treatment of AA amyloidosis, a long-term complication of various chronic inflammatory diseases associated with increased mortality, such as familial Mediterranian fever (FMF). Recently there are few reports pointing out that tocilizumab(TCZ), an anti IL-6 agent may be effective in AA amyloidosis resistant to conventional treatments. We report our data on the effect of TCZ in patients with FMF complicated with AA amyloidosis.